This inventor holds 1 USPTO granted patent. Top assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Chi Zhang: Innovator in Biomedicine
Introduction
Chi Zhang is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of biomedicine, particularly in the development of pharmaceutical compositions aimed at treating various types of tumors. His innovative work has the potential to impact cancer treatment positively.
Latest Patents
Chi Zhang holds a patent for a combined pharmaceutical composition for treating tumors. This patent, which is particularly relevant in the field of biomedicine, addresses the treatment of biliary tract tumors, liver cancer, triple-negative breast cancer, and lung cancer. The composition includes an anti-PD-L1 antibody and anlotinib, demonstrating effective anti-cancer activity.
Career Highlights
Throughout his career, Chi Zhang has worked with prominent companies in the pharmaceutical industry. He has been associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Nanjing Shunxin Pharmaceuticals Co., Ltd., both of which are part of the Chiatai Tianqing Pharmaceutical Group. His experience in these organizations has contributed to his expertise in developing innovative treatments.
Collaborations
Chi Zhang has collaborated with several professionals in his field, including Xiquan Zhang and Xunqiang Wang. These collaborations have likely enhanced his research and development efforts, leading to advancements in cancer treatment.
Conclusion
Chi Zhang is a distinguished inventor whose work in biomedicine is paving the way for new cancer therapies. His patent for a combined pharmaceutical composition showcases his commitment to improving treatment options for patients facing serious health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile